In addition,the potential for P2Y1 receptor antagonistsin Alzheimer’s disease has growing evidence and has recentlybeen reviewed.145 In a noteworthy studyby Boyer, osmotic minipumps were used either to infuse or intracerebroventricularly(i.c.v.)deliver the P2Y1R antagonist MRS2179 and demonstratedthat chronic P2Y1R inhibition reduces neuronal–astroglialnetwork hyperactivity in an Alzheimer’s disease (APP/PS1)transgenic mouse model. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.